BUSINESS WIRE
BOTHELL, Wash.--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company discovering new
drug therapies for eye diseases, today announced that data from a
preclinical study in retinopathy of prematurity (ROP) will be presented
at the Association for Research in Vision and Ophthalmology (ARVO)
Annual Meeting being held April 27 through May 1 in Fort Lauderdale,
Florida. The data will be presented by researchers from Children’s
Hospital Boston.
Presentation Details:
-
Date and Time: April 29, 2008, 8:30 a.m. –
10:15 a.m. EDT
-
Retinal Cell Biology Session: Retinal and Choroidal Angiogenesis II,
Hall B/C
-
Abstract Number: 2629 / A354
-
Poster Presentation: Effects of a Vitamin-A Derivative (AG-787-14-2)
on Retinal Function in Oxygen-Induced Retinopathy
-
Presenter: James D. Akula, Ph.D.
About Visual Cycle Modulation and its Impact on Blinding Eye Diseases
Visual cycle modulation may have the ability to impact multiple blinding
eye diseases. Acucela is developing an orally available drug that
inhibits the visual cycle potentially impacting the processes that can
lead to blinding eye diseases such as age-related macular degeneration
(AMD), diabetic retinopathy, retinopathy of prematurity and Stargardt
disease.
About Acucela
Acucela Inc. is focused on developing new drug therapies for eye
diseases, and particularly neurodegenerative retinal diseases such as
macular degeneration. The company has proprietary disease-specific
assays and technologies to identify and develop compounds that may
safely and effectively treat retinal diseases and injuries. The company’s
novel approaches have significant therapeutic potential to treat retinal
diseases such as Age-related Macular Degeneration (AMD) and Stargardt
disease, which affect 50 million people worldwide. The Bothell-based,
privately-held, biotechnology company was founded in 2002. For more
information, please visit http://www.acucela.com.
Forward-Looking Statement
This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, which may cause results to
differ materially from those set forth in the statements. The
forward-looking statements include statements regarding product
development. No forward-looking statement can be guaranteed, and actual
results may differ materially from those projected. Acucela undertakes
no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events, or otherwise.